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Objectives: Hydrogen sulﬁde (H2S) has been
described as a pharmacologic adjunct to minimize
ischemia-reperfusion injury (IRI). We sought to evaluate
the impact of H2S in a validated hindlimb ischemia model.
Methods: Forty swine (weight: 69 6 7.2 [standard
deviation] kg) were randomized to iliac artery occlusion
for 0, 3, or 6 hours of ischemia, followed by vessel repair,
and systemic infusion of H2S (10 mg/kg/h) or normal sa-
line for 2 hours after reperfusion. Animals were survived for
14 days with serial evaluation of systemic injury markers,
gait analysis, motor, and sensory nerve action potentials,
and histopathology.
Results: Baseline physiologic characteristics were
similar between groups. At 0 hours of ischemia, H2S
increased aspartate transaminase (AST; 125.68 6 58.36
IU/L vs 303.78 6 129.58 IU/L; P < .001), creatinine
phosphokinase (CK; 12014.17 6 8181.9 mg/L vs
28667.89 6 18883.18 mg/L; P < .001), and lactate dehy-
drogenase (LDH; 1107.67 6 754.13 U/L vs 1954.33 6
910.25 U/L; P¼ .004) on postoperative day (POD) 1. An-
imals receivingH2S at 3 hours of ischemia had lower AST on
POD1 (627.436 486.6 IU/Lvs 1162.436580.58 IU/L;
P < .05) and lower CK on POD 2 (27313.17 6 18151.19
mg/L vs 64230.71640503.18mg/L;P< .05). LDH levels
were signiﬁcantly lower in 3-hour and 6-hour ischemia H2S
groups on POD 1 (P< .05). No signiﬁcant differences were
observed between groups with respect to nerve action
potentials.
Conclusions: In a hindlimb ischemia model, intrave-
nous H2S administration during reperfusion mitigates the
systemic markers of IRI. The moderate ischemia group
experienced the greatest beneﬁt, with no beneﬁt seen in
minimal or severe ischemia groups.
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The Effect of VEGF Activating Transcription Factor in
Therapeutic Angiogenesis and Skeletal Muscle Fiber in
the Mouse With Hindlimb Ischemia
Yongjun Li1, Houzao Chen2, Lishan Lian1. 1Peking Union
Medical College Hospital, Beijing, China; 2Peking Union
Meducal College Basic Research, Beiijing, ChinaObjectives: To test whether vascular endothelial
growth factor (VEGF)-activating transcription factor
(ATF) stimulating the endogenous VEGF expression pro-
duces more mature neovessels and inﬂuences skeletal mus-
cle ﬁber type remodeling.
Methods: Ischemic limbs received VEGF-ATF treat-
ment or VEGF165 or placebo treatment after unilateral
femoral artery ligation and excision. Mice were euthanized
at 7, 14, and 21 days after injection. Limb blood ﬂow was
monitored serially by laser Doppler perfusion imaging.
VEGF protein expression was examined by Western blot-
ting. Capillary density, endothelial proliferation, and
apoptosis were examined using immunohistochemical
techniques. Besides that, according to rat mesenteric artery
immunoﬂuorescence, we observed neovessels maturity
with NG-2 for pericyte coverage. Finally, skeletal muscle ﬁ-
ber type was derived from myoﬁbrillar adenosine triphos-
phatase (mATPase) staining; moreover, the myosin heavy
chain (MHC) RNA isoform was tested with real-time po-
lymerase chain reaction (PCR).
Results: (1) The purposed gene was successfully con-
structed into the PVAX1 and the PcDNA3.0 plasmid. (2)
VEGF-ATF stimulated VEGF protein expression at 7 days
after compared with the VEGF165 control group. (3)
VEGF-ATF increased better perfusion recovery, and more-
over, produced a higher capillary density. (4) Rat mesenteric
artery immunoﬂuorescence indicated that the neovessels in
the VEGF-ATF group had more maturity because of the
whole pericyte coverage. (5) ATPase staining and MHC
real-time PCR results showed VEGF-AFP and VEGF165
both performed the remodeling of the muscle ﬁber type in
the gastrocnemius and soleus.
Conclusions: Intramuscular injection of VEGF-ATF
can perform therapeutic angiogenesis in the hindlimb
ischemic mouse model; moreover, stimulating the more
mature neovessles from the integrity. In addition, the mus-
cle ﬁber type shift might supply a potential method for the
intermittent distance development for the patients with pe-
ripheral artery disease.
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Objectives: Abdominal aortic aneurysm (AAA) is a life-
threatening chronic vascular disease. Previous work showed
that AAAs are attenuated in mice deﬁcient for C-C chemo-
kine receptor type 2 (CCR2), a critical regulator of mono-
cyte mobilization and migration. We evaluated the
therapeutic effect of propagermanium (PG), a CCR2 inhib-
itor, on formation and progression of experimental AAAs.
